ArticleInternational journal of hematology2026

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.

Taku Kikuchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.